API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Sogroya® (somapacitan) injection is a prescription human growth hormone analogue medicine, similar to the growth hormone made by the body, and is used to treat adults who do not make enough growth hormone.
Lead Product(s): Somapacitan
Therapeutic Area: Endocrinology Product Name: Sogroya
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
Sogroya® (somapacitan) injection is a prescription human growth hormone analogue medicine, similar to the growth hormone made by the body, and is used to treat adults who do not make enough growth hormone.
Lead Product(s): Somapacitan
Therapeutic Area: Endocrinology Product Name: Sogroya
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2022
Details:
Recommendation for marketing authorisation for Sogroya is based on results from the Phase III REAL 1 clinical trial programme, which investigated the efficacy and safety of Sogroya in AGHD.
Lead Product(s): Somapacitan
Therapeutic Area: Endocrinology Product Name: Sogroya
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021